1. Introduction {#sec1-molecules-24-01780}
===============

The molecular frameworks of diverse naturally-occurring cytotoxic compounds, such as smenospongine \[[@B1-molecules-24-01780]\], streptonigrin \[[@B2-molecules-24-01780]\], and mansouramicyn C \[[@B3-molecules-24-01780]\], contain the aminoquinoid moiety as their key structural component ([Figure 1](#molecules-24-01780-f001){ref-type="fig"}). In the field of synthetic cytotoxic aminoquinones, those derived from 1,4-naphthoquinone \[[@B4-molecules-24-01780],[@B5-molecules-24-01780],[@B6-molecules-24-01780],[@B7-molecules-24-01780],[@B8-molecules-24-01780]\] and their heterocyclic analogues \[[@B9-molecules-24-01780],[@B10-molecules-24-01780],[@B11-molecules-24-01780],[@B12-molecules-24-01780],[@B13-molecules-24-01780],[@B14-molecules-24-01780],[@B15-molecules-24-01780],[@B16-molecules-24-01780],[@B17-molecules-24-01780]\] have received considerable attention. However, the synthesis and cytotoxic evaluation of aminobenzoquinones has hitherto received little attention and was mainly focused on the 2,5-*bis*(arylamino)-1,4-benzoquinone derivatives as compounds **A** and **B**. The earlier findings of Verter and Rogers \[[@B18-molecules-24-01780]\] reported that specific 2,5-*bis*(alkylamino)-3,6-dimethoxy-1,4-benzoquinones, prepared from polyporic acid, increased the survival of L1210-bearing mice by 50%. In addition, Sarcoma 180 accumulated slower in treated Swiss albino mice than in control animals \[[@B19-molecules-24-01780]\]. Further studies, described by Mathew et al. \[[@B20-molecules-24-01780]\], on 2,5-*bis*(phenylamino)benzoquinone **A** and the corresponding chlorine analogue **B**, demonstrated a good in vitro inhibitory activity against human colon adenocarcinoma proliferation. Compound **B** was also found to be active against the leukemia L1210 screening in vitro.

It is worth noting that synthetic 2,5-*bis*(arylamino)-1,4-benzoquinones containing acyl and alkoxycarbonyl substituents at C-3 have been used as precursor of benz- and naphthoisoxazolequinones \[[@B21-molecules-24-01780],[@B22-molecules-24-01780],[@B23-molecules-24-01780]\]. Some of the members of these heterocycle series exhibit in vitro activity as radiosensitizers and cytotoxic properties. Here, we wish to report the synthesis of a broad variety of 3-acyl-2,5-*bis*(arylamino)-1,4-benzoquinones, in order to give information on their redox properties and in vitro cytotoxic activity on cancer cells.

2. Results and Discussion {#sec2-molecules-24-01780}
=========================

The members of the series of 3-acyl-2,5-*bis*(phenylamino)-1,4-benzoquinones ([Scheme 1](#molecules-24-01780-sch001){ref-type="scheme"}) were prepared from 1,4-benzoquinone and a set of aldehydes and phenylamines. The acylhydroquinone precursors **1a**--**q** were synthesized by the solar Friedel Crafts photoacylation of quinone **1** with aldehydes, according to our previously-reported procedure \[[@B24-molecules-24-01780]\]. The preparation of 3-acyl-2,5-*bis* (phenylamino)-1,4-benzoquinones **2a**--**q** was accomplished through a sequence involving: (a) Oxidation of the acylhydroquinones **1a**--**q**, to the respective acylquinones, with silver (I) oxide (2.5 equiv.) in dichloromethane (DCM) and (b) oxidative amination of the 2-acylquinones resulting in (b) with phenylamines (2 equiv.) in ethanol under aerobic conditions. This procedure provides the substituted benzoquinones **2a**--**q** in the yield range 47--74% ([Table 1](#molecules-24-01780-t001){ref-type="table"}), and is a modification of the procedure, described by Shäfer and Aguado in \[[@B25-molecules-24-01780]\], for the synthesis of compound **2a** and some of their substituted phenylamino analogs.

The structures of compounds **2a**--**q** were established by ^1^H- and ^13^C-nuclear magnetic resonance (NMR), bi-dimensional nuclear magnetic resonance (2D-NMR), and high resolution mass spectroscopy (HRMS). Heteronuclear multiple bond correlation (HMBC) experiments of the members of the series, as those of the representative congeners **2b** and **2p** ([Figure 2](#molecules-24-01780-f002){ref-type="fig"}), allowed us to establish the location of the substituents around the benzoquinone nuclei.

It is worth mentioning that inspection of minimal energy conformation of compounds **2b** and **2p**, performed by MM2 calculation (ChemBio3D 11.0, PerkinElmer, MA, USA), shows a co-planar orientation between the benzoquinone nucleus and the phenylamino substituent at C-5 ([Supplementary Materials](#app1-molecules-24-01780){ref-type="app"}). Furthermore, it was also observed that rotation of the substituents linked to the 2,3-quinone double bond are strongly hindered ([Figure 3](#molecules-24-01780-f003){ref-type="fig"}).

The members of the 3-acyl-2,5-*bis*(phenylamino)-1,4-benzoquinone series **2a**--**q** were evaluated for their half-wave potentials (E^I^ ~1/2~ and E^II^ ~1/2~). They were measured by cyclic voltammetry in acetonitrile at room temperature, using a platinum electrode and 0.1 M tetraethylamoniumtetrafluoroborate as the supporting electrolyte \[[@B26-molecules-24-01780]\]. The voltammograms were run in the potential range from 0.0 to −2.0 V versus non-aqueous Ag/Ag^+^. The cathodic peaks related to the reduction of quinone, and the anodic one due to its re-oxidation, were observed for the compounds as well-defined quasi-reversible waves.

The E^I^ ~1/2~ values for the first one-electron, which is related with the formation of the semiquinone radical anion, fell within the range of −850 to −500 mV. The E^I^ ~1/2~ values for the second one-electron transfer, corresponding to the dianion formation \[[@B27-molecules-24-01780],[@B28-molecules-24-01780]\], were located within the range of −1170 to −860 mV ([Table 1](#molecules-24-01780-t001){ref-type="table"}). Taking into account the notable differences of the E~1/2~ values for each of the one-electron transfer processes, it is evident that they are due to the push-pull electronic effects of the substituents located in the 1,4-benzoquinone nucleus. [Table 1](#molecules-24-01780-t001){ref-type="table"}, regarding the E^I^ ~1/2~ and E^II^ ~1/2~ values of the unsubstituted phenylamino members **2a**--**h**, indicates that the nature of the acyl substituents mainly affects the second half-wave potential (ΔE^II^ ~1/2~ = 300 mV) over the first one (ΔE^II^ ~1/2~ = 90 mV). The effect of the insertion of methoxy substituents into the 3-acyl-2,5-*bis*(phenylamino)-1,4-benzoquinone scaffold, as in compounds **2i**--**2m**, was related to a significant cathodic shift of the E^I^ ~1/2~ when compared to E^II^ ~1/2~. This fact could be attributed to the donor effect of the 3,4,5-trimethoxyphenyl group, which is transmitted to the quinonoid nucleus through the amino group.

The effects on redox properties and lipophilia by either electron-donating or electron-withdrawing groups in the 3-acyl-2,5-*bis*(phenylamino)-1,4-benzoquinone scaffold (compounds **2i**--**2m** versus **2n**--**2q**) were also examined. [Table 1](#molecules-24-01780-t001){ref-type="table"} shows that the methoxy group (as in compounds **2i**--**2m**) led to increased values of E^I^ ~1/2~ (−610 to −850 mV) but reduced values of ClogP (−0.2 to 1.19). Conversely, the fluorine group (as in compounds **2n**--**2q**) led to decreased values of E^I^ ~1/2~ (−550 to −730 mV) but enhanced values of ClogP (0.88 to 2.26). As compared to previous series, it should be noted that the E^I^ ~1/2~ values of the unsubstituted phenylamino members **2a**--**h** ranged between −500 and −590 mV.

The 3-acyl-2,5-*bis*(phenylamino)-1,4-benzoquinones **2a**--**q** were evaluated for their in vitro cytotoxic activities against normal human embryonic kidney cells (HEK-293 cells) and two human cancer cell lines (T24 and DU-145 cells) in 72 h drug exposure assays. The cytotoxic activities of the new compounds were measured using conventional microculture tetrazolium reduction assays \[[@B29-molecules-24-01780]\]. The cytotoxic activities are expressed in terms of IC~50~. Doxorubicin, a clinically used anti-cancer agent, was taken as a positive control. The cytotoxic activity data are summarized in [Table 2](#molecules-24-01780-t002){ref-type="table"}.

Regarding the cytotoxicity of aminoquinones, it should be noted that the DU-145 cells were more sensitive than T24 and HEK-293 cells. When comparing the IC~50~ values calculated for the most active aminoquinones in both cancer cell lines, their activity ranged from 16.3 to 51.80 µM. Such values were at least one order of magnitude higher than that obtained with doxorubicin (0.43 and 0.93 µM in T24 and DU-145 cells, respectively). The unsubstituted phenylamino members **2a**--**2h** were largely more active than the compounds **2i**--**2q**, showing that the substitution of both aniline groups---by either methoxy (electron donating effect) or fluorine (electron withdrawal effect)---decreased the cytotoxicity of the aminoquinones. Among the series **2a**--**2h**, the compounds **2c** (IC~50~ values of 16.3 and 45.2 µM in T24 and DU-145 cells, respectively) and **2d** (IC~50~ values of 34.0 and 23.5 µM in T24 and DU-145 cells, respectively) were the most active; displaying, in addition, a highly selective effect, as HEK-293 cells were affected only at doses higher than 100 µM. Moreover, within the same series, compounds **2f** and **2g** showed similar cytotoxic activities to previous compounds, but with a much lower selectivity. Outside this series, compound **2l** was also active, but without any selectivity as it affected both HEK-293 and cancer cells. Thus, it may be concluded that, among all the tested aminoquinones, congeners **2c** and **2d** displayed the best cytotoxic activities, exhibiting high selectivity and lipophilicity values. Therefore, they represent lead-molecules for further investigations in exploring both intracellular targets as well as their molecular mechanism of action.

In order to gain information about potential molecular targets, a preliminary assay for gene expression was conducted. To this end, some genes were selected, regarding their key role in cell survival, for instance mTOR, TP53, TNF, and so on. [Table 3](#molecules-24-01780-t003){ref-type="table"} shows the relative expression levels of the genes implicated in anti-cancer effects in T24 cells after treatment with **2c** and **2d**.

Compound **2c** (and, to a lesser extent, **2d**) enhanced the expression of the TNF gene. Prior to drawing a definitive conclusion, such an increase in gene expression should be further confirmed by measuring its protein levels and activity. Nevertheless, it should be emphasized that a local increase in TNF concentration is not only associated with an inflammatory response, but also with an immunogenic response able to activate tumor-specific cytotoxic T lymphocytes, which can seek out and destroy tumor cells and reduce tumor lesions \[[@B30-molecules-24-01780]\]. In this context, the compounds **2c** and **2d** display a potential application in cancer immunotherapy that deserves to be further investigated.

3. Materials and Methods {#sec3-molecules-24-01780}
========================

3.1. General Information {#sec3dot1-molecules-24-01780}
------------------------

All the solvents and reagents were purchased from different companies, such as Aldrich (St. Louis, MO, USA) and Merck (Darmstadt, Germany), and were used as supplied. Melting points (mp) were determined on a Stuart Scientific SMP3 (Staffordshire, UK) apparatus and are un-corrected. The IR spectra were recorded on an FT IR Bruker spectrophotometer, model Vector 22 (Bruker, Rheinstetten, Germany), using KBr disks, and the wave numbers are given in cm^−1^. ^1^H- and ^13^C-NMR spectra were recorded on a Bruker Avance-400 instrument (Bruker, Ettlingen, Germany) in CDCl~3~ or DMSO-*d*~6~ at 400 and 100 MHz, respectively. Chemical shifts are expressed in ppm downfield relative to tetramethylsilane, and the coupling constants (*J*) are reported in Hertz. Data for the ^1^H-NMR spectra are reported as follows: s = singlet, br s = broad singlet, d = doublet, m = multiplet, and the coupling constants (*J*) are in Hz. Bi-dimensional NMR techniques and distortion-less enhancement by polarisation transfer (DEPT) were used for the signal assignment. Chemical shifts are expressed in ppm downfield relative to tetramethylsilane, and the coupling constants (*J*) are reported in Hertz. The HRMS data for all final compounds were obtained using a LTQ-Orbitrap mass spectrometer (Thermo-Fisher Scientific, Waltham, MA, USA) with the analysis performed using an atmospheric-pressure chemical ionization (APCI) source, operated in positive mode. Silica gel Merck 60 (70--230 mesh, from Merck) was used for preparative column chromatography and thin layer chromatography (TLC) aluminum foil 60F~254~ was used for analytical thin layer chromatography. The acylbenzohydroquinones (**1a**--**q**) were prepared according to a previously-reported procedure \[[@B24-molecules-24-01780]\].

3.2. Chemistry {#sec3dot2-molecules-24-01780}
--------------

### Preparation of 3-Acyl-2,5-bis(phenylamino)-1,4-benzoquinones **2a**--**q**, General Procedure. {#sec3dot2dot1-molecules-24-01780}

Suspensions of the acylhydroquinones **1a**--**q** (1 equiv.), Ag~2~O (2.0 equiv.) and MgSO~4~ anhydrous (300 mg) in dichloromethane (30 mL) were left with stirring for 30 min at room temperature (rt). The mixtures were filtered, the solids were washed with dichloromethane (3 × 25 mL), and the filtrates were evaporated under reduced pressure. The residues were dissolved in ethanol, the phenylamines (2 equiv.) were added to the solutions, and the mixtures were left with stirring at rt for 24 h. The solvents were removed under reduced pressure and the residues were column-chromatographed over silica gel (petroleum ether/EtOAc) to yield the corresponding pure 3-acyl-2,5-*bis*(phenylamino)-1,4-benzoquinones **2a**--**q**.

*3-Acetyl-2,5-bis(phenylamino)-1,4-benzoquinone***2a** (64%); red solid; mp: 200--201 °C. ^1^H-NMR (DMSO-*d*~6~): δ 2.30 (s, 1H, Me), 5.80 (s, 1H, quinone), 7.22 (m, 4H, arom.), 7.36 (m, 4H, arom.), 7.45 (dd, 2H, *J* = 7.5, 7.7 Hz, arom.), 9.55 (s, 1H, 5-N**H**Ph), 11.31 (br s, 1H, 2-N**H**Ph). ^13^C-NMR (DMSO-*d*~6~): δ 31.9, 96.4, 109.1, 123.9 (3C), 124.2 (2C), 125.8, 126.2, 128.7 (2C), 129.3 (2C), 137.6, 139.2, 147.6, 178.3, 178.5, 199.3. HRMS (APCI): \[M + H\]^+^ calcd. for C~20~H~16~N~2~O~3~: 332.11609; found 332.11359.

*3-Butiryl-2,5-bis(phenylamino)-1,4-benzoquinone***2b** (56%); red solid; mp: 115--116 °C. ^1^H-NMR (DMSO-*d*~6~): δ 0.78 (t, 3H, *J* = 7.4 Hz, -CH~2~-CH~2~-**CH~3~**), 1.23 (m, 2H, -CH~2~-**CH~2~**-CH~3~), 2.63 (t, 2H, *J* = 7.4 Hz, -**CH~2~**-CH~2~-CH~3~), 5.81 (s, 1H, quinone), 7.15 (d, 2H, *J* = 7.4 Hz, H-arom.), 7.20 (t, 1H, *J* = 7.4 Hz, H-arom.), 7.25 (t, 1H, *J* = 7.3 Hz, H-arom.), 7.32 (t, 2H, *J* = 7.8 Hz, H-arom.), 7.38 (d, 2H, *J* = 7.4 Hz, H-arom.), 7.45 (t, 2H, *J* = 7.8 Hz, H-arom.), 9.51 (s, 1H, 5-N**H**Ph), 10.85 (br s, 1H, 2-N**H**Ph). ^13^C-NMR (DMSO-*d*~6~): δ 13.7, 16.6, 45.6, 96.0, 109.2, 123.9 (2C), 124.4 (2C), 125.8, 126.2, 128.7 (2C), 129.3 (3C), 137.6, 139.0, 147.5, 178.2, 178.8, 201.6. HRMS (APCI): \[M + H\]^+^ calcd. for C~22~H~20~N~2~O~3~: 360.14739; found 360.15469.

*3-Hexanoyl-2,5-bis(phenylamino)-1,4-benzoquinone***2c** (57%); brown solid; mp: 140--141 °C. ^1^H-NMR (DMSO-*d*~6~): δ 0.83 (t, 3H, *J* = 7.1 Hz, -CH~2~-CH~2~-CH~2~-CH~2~-**CH~3~**), 1.17 (m, 6H, -CH~2~-**CH~2~-CH~2~-CH~2~**-CH~3~), 2.63 (t, 2H, *J* = 7.0 Hz, -**CH~2~**-CH~2~-CH~2~-CH~2~-CH~3~), 5.80 (s, 1H, quinone), 7.14 (d, 2H, *J* = 7.4 Hz, H-arom.), 7.20 (t, 1H, *J* = 7.4 Hz, H-arom.), 7.25 (t, 1H, *J* = 7.3 Hz, H-arom.), 7.32 (t, 2H, *J* = 7.7 Hz, H-arom.), 7.38 (d, 2H, *J* = 7.4 Hz, H-arom.), 7.45 (t, 2H, *J* = 7.8 Hz, H-arom.), 9.51 (s, 1H, 5-N**H**Ph), 10.79 (br s, 1H, 2-N**H**Ph). ^13^C-NMR (DMSO-*d*~6~): δ 13.8, 22.0, 22.8, 30.8, 43.5, 95.9, 109.3, 123.9 (2C), 124.4 (2C), 125.8, 126.2, 128.8 (2C), 129.3 (3C), 137.6, 139.0, 147.5, 178.2, 178.8, 201.6. HRMS (APCI): \[M + H\]^+^ calcd. for C~24~H~24~N~2~O~3~: 388.17869; found 388.18599.

*3-Octanoyl-2,5-bis(phenylamino)-1,4-benzoquinone***2d** (59%); brown solid; mp: 91--92 °C. ^1^H-NMR (DMSO-*d*~6~): δ 0.86 (t, 3H, *J* = 7.0 Hz, -(CH~2~)~6~C**[H]{.ul}**~3~, 1.23 (m, 10H, -CH~2~-(C**[H]{.ul}**~2~)~5~CH~3~), 2.63 (t, 2H, *J* = 6.5 Hz, -C**[H]{.ul}**~2~(CH~2~)~5~CH~3~), 5.81 (s, 1H, quinone), 7.14 (d, 2H, *J* = 7.5 Hz, H-arom.), 7.19 (t, 1H, *J* = 7.4 Hz, H-arom.), 7.25 (t, 1H, *J* = 7.2 Hz, H-arom.), 7.32 (t, 2H, *J* = 7.7 Hz, H-arom.), 7.38 (d, 2H, *J* = 7.4 Hz, H-arom.), 7.45 (t, 2H, *J* = 7.8 Hz, H-arom.), 9.51 (s, 1H, 5-N**H**Ph), 10.81 (br s, 1H, 2-N**H**Ph). ^13^C-NMR (DMSO-*d*~6~): δ 13.9, 22.0, 23.1, 28.5, 28.6, 31.1, 43.6, 95.9, 109.3, 123.8 (2C), 124.4 (2C), 125.8, 126.1, 128.7 (2C), 129.3 (3C), 137.6, 139.0, 147.5, 178.2, 178.8, 201.6. HRMS (APCI): \[M + H\]^+^ calcd. for C~26~H~28~N~2~O~3~: 416.20999; found 416.21710.

*3-(3,4-Dimethoxybenzoyl)-2,5-bis(phenylamino)-1,4-benzoquinone***2e** (55%); gray solid; mp: 230.5--231.5 °C. ^1^H-NMR (DMSO-*d*~6~): δ 3.67 (s, 3H, OMe), 3.82 (s, 3H, OMe), 5.91 (s, 1H, quinone), 6.81 (t, 3H, *J* = 7.6 Hz, H-arom.), 6.94 (m, 4H, H-arom.), 7.26 (t, 2H, *J* = 7.2 Hz, H-arom.), 7.41 (d, 2H, *J* = 7.7 Hz, H-arom.), 7.46 (t, 2H, *J* = 7.4 Hz, H-arom.), 9.42 (s, 1H, 5-N**H**Ph), 9.54 (br s, 1H, 2-N**H**Ph). ^13^C-NMR (DMSO-*d*~6~): δ 55.3, 55.7, 95.3, 107.7, 109.9, 110.3, 123.8 (2C), 124.0, 125.7 (2C), 125.7, 126.0, 128.0 (2C), 129.3 (3C), 130.9, 137.7, 146.0, 147.3, 148.3, 152.8, 178.4, 179.3, 191.5. HRMS (APCI): \[M + H\]^+^ calcd. for C~27~H~22~N~2~O~5~: 454.15287; found 454.15964.

*3-(3,4,5-Trimethoxybenzoyl)-2,5-bis(phenylamino)-1,4-benzoquinone***2f** (58%); brown solid; mp: 216.5--217.5 °C. ^1^H-NMR (CDCl~3~): δ 3.80 (s, 6H, OMe), 3.89 (s, 3H, OMe), 6.19 (s, 1H, quinone), 6.74 (s, 2H, H-arom.), 6.82 (m, 2H, H-arom.), 7.06 (m, 3H, H-arom.), 7.28 (m, 3H, H-arom.), 7.44 (t, 2H, *J* = 7.8 Hz, H-arom.), 8.23 (s, 1H, 5-N**H**Ph), 8.48 (br s, 1H, 2-N**H**Ph). ^13^C-NMR (CDCl~3~): δ 56.4 (2C), 61.0, 106.5 (2C), 123.1 (3C), 125.7 (2C), 126.6, 127.1, 129.0 (2C), 129.9 (3C), 133.1, 136.7, 136.9, 142.8, 146.0, 146.7, 152.9 (2C), 178.3, 179.3, 191.8. HRMS (APCI): \[M + H\]^+^ calcd. for C~28~H~24~N~2~O~6~: 484.16344; found 484.16364.

*3-(Furan-2-carbonyl)-2,5-bis(phenylamino)-1,4-benzoquinone***2g** (56%); brown solid; mp: 141.5--142.5 °C. ^1^H-NMR (DMSO-*d*~6~): δ 5.89 (s, 1H, quinone), 6.88 (d, 2H, *J* = 7.4 Hz, H-arom.), 7.01 (m, 3H, H- arom), 7.09 (t, 1H, *J* = 4.3 Hz, H-arom.), 7.26 (t, 1H, *J* = 7.1 Hz, H-arom.), 7.41 (d, 2H, *J* = 7.7 Hz, H-arom.), 7.46 (t, 2H, *J* = 7.7 Hz, H-arom.), 7.58 (d, 1H, *J*= 3.5 Hz, H-arom.), 7.84 (d, 1H, *J* = 4.7 Hz, H-arom.), 9.45 (s, 1H, 5-N**H**Ph), 9.65 (br s, 1H, 2-N**H**Ph). ^13^C-NMR (DMSO-*d*~6~): δ 95.3, 107.7, 123.9 (2C), 125.6 (2C), 125.8, 126.2, 127.9, 128.0 (2C), 129.3 (2C), 133.9, 134.8, 137.5, 137.6, 145.2, 146.0, 147.4, 178.1, 179.0, 184.8. HRMS (APCI): \[M + H\]^+^ calcd. for C~23~H~16~N~2~O~4~: 384.11101; found 384.11164.

*3-(Thiophen-2-carbonyl)-2,5-bis(phenylamino)-1,4-benzoquinone***2h** (60%); brown solid; mp: 245--246 °C. ^1^H-NMR (DMSO-*d*~6~): δ 5.88 (s, 1H, quinone), 6.57 (d, 1H, *J* = 3.3 Hz, H-arom.), 6.90 (m, 2H, H- arom), 7.00 (d, 1H, *J* = 3.2 Hz, H-arom.), 7.04 (d, 3H, *J* = 5.1 Hz, H-arom.), 7.26 (t, 1H, *J* = 7.1 Hz, H-arom.), 7.40 (d, 2H, *J* = 7.9 Hz, H-arom.), 7.46 (t, 2H, *J* = 7.5 Hz, H-arom.), 7.81 (s, 1H, H-arom.), 9.46 (s, 1H, 5-N**H**Ph), 9.68 (br s, 1H, 2-N**H**Ph). ^13^C-NMR (DMSO-*d*~6~): δ 95.3, 107.2, 112.5, 118.2, 123.9 (2C), 125.2 (2C), 125.8, 126.3, 128.1 (2C), 129.3 (2C), 137.6, 137.7, 146.2, 146.8, 147.4, 153.1, 178.1, 179.0, 180.0. HRMS (APCI): \[M + H\]^+^ calcd. for C~23~H~16~N~2~O~3~S: 400.08816; found 400.09555.

*3-Benzoyl-2,5-bis-\[(3,4,5-trimethoxyphenyl)amino\]-1,4-benzoquinone***2i** (74%); brown solid; mp: 224--225 °C. ^1^H-NMR (CDCl~3~) δ: 3.54 (s, 3H, OMe), 3.76 (s, 3H, OMe), 3.80 (s, 3H, OMe), δ: 3.87 (s, 9H, 3 × OMe), 5.97 (s, 2H, H-arom.) 6.14 (s, 1H, quinone), 6.49 (s, 2H, H-arom.), 7.31 (m, 1H, H-arom.), 7.45 (m, 1H, H-arom.), 7.56 (d, 2H, *J* = 7.3 Hz, H-arom.), 8.16 (s, 1H, 5-N**H**Ph), 8.42 (br s, 1H, 2-N**H**Ph). ^13^C-NMR (CDCl~3~) δ: 55.8 (2C), 56.4 (2C), 60.9, 61.1, 95.9, 101.0 (2C), 102.9 (2C), 107.0, 128.4 (2C), 128.8 (2C), 132.3, 132.5, 133.0, 136.7, 136.9, 137.6, 145.9, 147.0, 153.2 (2C), 154.1 (2C), 178.2, 179.0, 192.9. HRMS (APCI): \[M + H\]^+^ calcd. for C~31~H~30~N~2~O~9~: 574.19513; found 574.20187.

*3-(4-Methoxybenzoyl)-2,5-bis-\[(3,4,5-trimethoxyphenyl)amino\]-1,4-benzoquinone***2j** (57%); red solid; mp: 190--191 °C. ^1^H-NMR (CDCl~3~) δ: 3.57 (s, 6H, 2 × OMe), 3.77 (s, 3H, OMe), 3.82 (s, 3H, OMe), 3.87 (s, 9H, 3 × OMe), 5.99 (s, 2H, H-arom.), 6.11 (s, 1H, quinone), 6.49 (s, 2H, H-arom.), 6.77 (d, 2H, *J* = 8.8 Hz, H-arom.), 7.53 (d, 2H, *J* = 8.8 Hz, H-arom.), 8.16 (s, 1H, 5-N**H**Ph), 8.37 (br s, 1H, 2-N**H**Ph). ^13^C-NMR (CDCl~3~) δ: 55.6, 55.8 (2C), 56.4 (2C), 60.8, 61.1, 95.8, 101.0 (2C), 102.9 (2C), 107.3, 113.5 (2C), 131.0, 131.2 (2C), 132.4, 132.6, 136.7, 136.8, 145.6, 147.0, 153.0 (2C), 154.0 (2C), 163.5, 178.2, 179.2, 191.3. HRMS (APCI): \[M + H\]^+^ calcd. for C~32~H~32~N~2~O~10~: 604.20570; found 604.21238.

*3-(4-Hydroxy-3-methoxybenzoyl)-2,5-bis-\[(3,4,5-trimethoxyphenyl)amino\]-1,4-benzoquinone***2k** (63%); brown solid; mp: 152--152 °C. IR (KBr) ν~max~ cm^--1^: 3246 (N-H), 3245 (N-H), 1662 (C=O), 1649 (C=O), 1636 (C=O). ^1^H-NMR (CDCl~3~) δ: 3.61 (s, 6H, 2 × OMe), 3.75(s, 3H, OMe), 3.85(s, 3H, OMe), 3.88(s, 3H, OMe), 3.89 (s, 6H, 2 × OMe), 5.99 (s, 2H, H-arom.), 6.13 (s, 2H, quinone + OH), 6.50 (s, 2H, H-arom.), 6.81 (d, 1H, *J* = 8.2 Hz, H-arom.), 6.95 (d, 1H, *J* = 1.8 Hz, arom), 7.25 (dd, 1H, *J* = 8.2, 1.9 Hz, arom), 8.15 (s, 1H, 5-N**H**Ph), 8.34 (br s, 1H, 2-N**H**Ph). ^13^C-NMR (CDCl~3~) δ: 55.9 (2C), 56.2, 56.5 (2C), 61.0, 61.2, 95.8, 101.0 (2C), 103.1 (2C), 107.3, 109.3, 113.2, 125.2, 131.0, 132.4, 132.6, 136.7, 145.7, 146.8, 147.1, 150.6 (2C), 153.1 (2C), 154.1 (2C), 178.2, 179.2, 191.6. HRMS (APCI): \[M + H\]^+^ calcd. for C~32~H~32~N~2~O~11~: 620.20061; found 620.20726.

*3-(Furan-2-carbonyl)-2,5-bis-\[(3,4,5-trimethoxyphenyl)amino\]-1,4-benzoquinone***2l** (67%); red solid; mp: 202--203 °C. ^1^H-NMR (CDCl~3~) δ: 3.66 (s, 6H, 2 × OMe), 3.78(s, 3H, OMe), 3.87 (s, 3H, OMe), 3.88 (s, 6H, 2xOMe), 6.12 (s, 1H, quinone), 6.17 (s, 2H, H-arom.), 6.44 (dd, 1H, *J* = 3.6, 1.6 Hz, H-arom.), 6.49 (s, 2H, H-arom.), 6.88 (dd, 1H, *J* = 3.6, 0.8 Hz, H-arom.), 7.47 (d, 1H, *J* = 1.6, 0.8 Hz, H-arom.), 8.11 (s, 1H, 5-N**H**Ph), 8.47 (s, 1H, 2-N**H**Ph). ^13^C-NMR (CDCl~3~) δ: 56.0 (2C), 56.4 (2C), 61.0, 61.1, 96.0, 100.9 (2C), 102.2 (2C), 106.7, 112.9, 117.4, 132.4, 132.5, 136.7, 137.1, 145.7, 146.1, 147.1, 153.4 (2C), 153.5, 154.1 (2C), 177.8, 178.9, 180.2. HRMS (APCI): \[M + H\]^+^ calcd. for C~29~H~28~N~2~O~10~: 564.17440; found 564.18120.

*3-(Thiophen-2-carbonyl)-2,5-bis-\[(3,4,5-trimethoxyphenyl)amino\]-1,4-benzoquinone***2m** (64%); red solid; mp: 174.5--175.5 °C. ^1^H-NMR (CDCl~3~) δ: 3.62 (s, 6H, 2 × OMe), 3.79 (s, 3H, OMe), 3.87 (s, 3H, OMe), 3.88 (s, 6H, 2 × OMe), 6.09 (s, 2H, H-arom.), 6.12 (s, 1H, quinone), 6.49(s, 2H, H-arom.), 7.0 (dd, 1H, *J* = 4.9, 3.8 Hz, H-arom.), 7.43 (dd, 1H, *J* = 3.8, 1.2 Hz, H-arom.), 7.55 (dd, 1H, *J* = 4.9, 1.2 Hz, H-arom.), 8.15 (s, 1H, 5-N**H**Ph), 8.44 (s, 1H, 2-N**H**Ph). ^13^C-NMR (CDCl~3~) δ: 56.0 (2C), 56.4 (2C), 61.0, 61.2, 95.9, 101.0 (2C), 103.0 (2C), 107.5, 127.6, 132.2, 132.5, 133.2, 134.6, 136.7, 137.1, 145.6, 145.7, 147.0, 153.3 (2C), 154.1 (2C), 177.8, 178.9, 184.5. HRMS (APCI): \[M + H\]^+^ calcd. for C~29~H~28~N~2~O~9~S: 580.15155; found 580.15880.

*3-Benzoyl-2,5-bis-\[(4-fluorophenyl)amino\]-1,4-benzoquinone***2n** (47%); brown solid; mp: 250--251 °C. ^1^H-NMR (CDCl~3~) δ: 6.02 (s, 1H, quinone), 6.68 (t, 2H, *J* = 8.5 Hz, H-arom.), 6.79 (dd, 2H, *J* = 8.7, 4.8 Hz, H-arom.), 7.14 (m, 2H, H-arom.), 7.24 (m, 2H, H-arom.), 7.33 (t, 2H, *J* = 7.6 Hz, H-arom.), 7.48 (t, 1H, *J* = 7.4 Hz, H-arom.), 7.54 (d, 1H, *J* = 1.4 Hz, H-arom.), 7.57 (m, 1H, H-arom.), 8.06 (s, 1H, 5-N**H**Ph), 8.41 (br s, 1H, 2-N**H**Ph). ^13^C-NMR (CDCl~3~) δ: 95.7, 107.5, 115.8, 116.1, 116.7 (2C), 117.1, 125.3, 125.4, 127.7, 127.8, 128.5 (2C), 128.8 (2C), 132.6, 132.7, 132.8, 132.9, 133.4, 137.6, 147.1, 178.4, 179.2, 193.1. HRMS (APCI): \[M + H\]^+^ calcd. for C~25~H~16~F~2~N~2~O~3~: 430.11290; found 430.11942.

*3-(4-Methoxybenzoyl)-2,5-bis-\[(4-fluorophenyl)amino\]-1,4-benzoquinone***2ñ** (62%); brown solid; mp: 239--240 °C. ^1^H-NMR (CDCl~3~) δ: 3.86 (s, 3H, OMe), 6.00 (s, 1H, quinone), 6.70 (t, 2H, *J* = 8.5 Hz, H-arom.), 6.81 (dd, 4H, *J* = 8.8, 4.0 Hz, H-arom.), 7.13 (t, 2H, *J* = 8.5 Hz, H-arom.), 7.23 (m, 2H, H-arom.), 7.53 (d, 2H, *J* = 8.9 Hz, H-arom.), 8.09 (s, 1H, 5-N**H**Ph), 8.33 (br s, 1H, 2-N**H**Ph). ^13^C-RMN (CDCl~3~) δ: 55.5, 95.5, 107.7, 113.5 (3C), 115.5, 116.6, 116.9, 125.2, 125.3, 127.6, 127.7, 130.8, 131.2 (2C), 132.4, 132.5, 132.7, 132.7, 145.8, 147.0, 163.7, 178.3, 179.2, 191.4. HRMS (APCI): \[M + H\]^+^ calcd. for C~26~H~18~F~2~N~2~O~4~: 460.12346; found 460.13003.

*3-(4-Hydroxy-3-methoxybenzoyl)-2,5-bis-\[(4-fluorophenyl)amino\]-1,4-benzoquinone***2o** (52%); brown solid; mp: 221--222 °C. ^1^H-NMR (CDCl~3~) δ: 3.85 (s, 3H, OMe), 6.01 (s, 1H, OH), 6.11 (s, 1H, quinone), 6.79 (m, 5H, H-arom.), 6.95 (m, 1H, H-arom.), 7.15 (m, 2H, H-arom.), 7.26 (m, 4H, H-arom.), 8.09 (s, 1H, 5-N**H**Ph), 8.28 (s, 1H, 2-N**H**Ph). ^13^C-NMR (CDCl~3~) δ: 56.1, 95.6, 107.8, 109.3, 113.6, 115.6, 115.9, 116.7, 117.0, 125.3, 125.4, 125.5, 128.1, 128.2, 130.9, 132.5, 132.6, 132.7, 132.8, 145.9, 146.8, 147.1, 150.8, 178.4, 179.3, 191.6. HRMS (APCI): \[M + H\]^+^ calcd. for C~26~H~18~F~2~N~2~O~5~: 476.11838; found 476.12468.

*3-(Furan-2-carbonyl)-2,5-bis-\[(4-fluorophenyl)amino\]-1,4-benzoquinone***2p** (49%); brown solid; mp: 271.5--272.5 °C. ^1^H-NMR (DMSO-*d*~6~) δ: 5.78(s, 1H, quinone), 6.59 (m, 1H, arom.), 6.90 (m, 4H, H-arom.), 7.05 (d, 1H, *J* = 3.4 Hz, H-arom.), 7.30 (t, 2H, *J* = 8.8 Hz, H-arom.), 7.43 (dd, 4H, *J* = 9.0, 5.0 Hz, H-arom.), 7.85 (m, 1H, H-arom.), 9.50(s, 1H, 5-N**H**Ph), 9.67 (s, 1H, 2-N**H**Ph). ^13^C-NMR (DMSO-*d*~6~) δ: 95.1, 107.2, 112.6, 114.5, 115.0, 116.0, 116.3, 129.2, 126.3 (2C), 127.7, 127.9, 133.9 (2C), 134.0, 134.1, 146.6, 147.1, 147.7, 153.0, 178.1, 178.9, 180.1. HRMS (APCI): \[M + H\]^+^ calcd. for C~23~H~14~F~2~N~2~O~4~: 420.09216; found 420.09920.

*3-(Thiophen-2-carbonyl)-2,5-bis-\[(4-fluorophenyl)amino\]-1,4-benzoquinone***2q** (55%); brown solid; mp: 278--279 °C. ^1^H-NMR (CDCl~3~) δ: 5.78(s, 1H, quinone), 6.86 (m, 4H, H-arom.), 7.10 (s, 1H, H-arom.), 7.36 (m, 4H, H-arom.), 7.60 (s, 1H, H-arom.), 7.89 (s, 1H, H-arom.), 9.48 (s, 1H, 5-N**H**Ph), 9.63 (s, 1H, 2-N**H**Ph). ^13^C-NMR (CDCl~3~) δ: 95.1, 107.7, 114.7, 115.0, 116.0, 116.3, 126.2, 126.3, 128.1 (2C), 128.2, 133.7, 133.8, 133.9, 134.0, 134.3, 135.2, 145.1, 146.3, 147.7, 178.1, 178.9, 185.0. HRMS (APCI): \[M + H\]^+^ calcd. for C~23~H~14~F~2~N~2~O~3~S: 436.06932; found 436.07638.

3.3. Biological Assays {#sec3dot3-molecules-24-01780}
----------------------

### 3.3.1. Cell Lines and Cell Cultures {#sec3dot3dot1-molecules-24-01780}

Human cancer cell lines T24 (bladder) and DU-145 (prostate), and non-tumor HEK-293 cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). The cultures were maintained at a density of 1× 10^5^ cells/mL and the medium was changed at 48- to 72-h intervals. They were cultured in high-glucose Dulbecco's modified Eagle medium (Gibco, Grand Island, NY, USA) supplemented with 10% fetal calf serum, penicillin (100 U/mL), and streptomycin (100 μg/mL). All cultures were kept at 37 °C in 95% air/5% CO~2~ at 100% humidity. Phosphate-buffered saline (PBS) was purchased from Gibco. Cells were incubated at the indicated times at 37 °C, with or without quinones at various concentrations.

### 3.3.2. Cytotoxic Assays {#sec3dot3dot2-molecules-24-01780}

The cytotoxicity of the quinones was assessed by following the reduction of MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) to formazan blue \[[@B31-molecules-24-01780]\]. Cells were seeded into 96-well plates at a density of 10,000 cells/well for 24 h and then incubated for 48 h, with or without the quinone derivatives. Doxorubicin was used as the standard chemotherapeutic agent (positive control). Cells were then washed twice with warm PBS and incubated with MTT (0.5 mg/mL) for 2 hours at 37 °C. Blue formazan crystals were solubilized by adding 100 µL DMSO/well, and the optical density of the coloured solutions was subsequently read at 550 nm. Results are expressed as percentage of MTT reduction, compared to untreated control conditions. The IC~50~ values were calculated using the GraphPad Prism software (San Diego, CA, USA).

### 3.3.3. Quantitative real-time PCR (qPCR) Assay {#sec3dot3dot3-molecules-24-01780}

The T24 cells were cultured as previously mentioned. They were seeded into 6-well plates (2 × 10^5^ cells/well) and, after 24 h of incubation, they were treated for 48 h with **2c** and **2d** (at 32 and 68 µM, respectively). Afterwards, they were washed with phosphate-buffered saline. The cellular lysate was prepared with E.Z.N.A.® RNA-Lock Reagent (Omega Bio-tek, Norcross, GA, USA) to preserve and immediately stabilize the total RNA for the subsequent gene expression assays. The total RNA isolated from the cells using the E.Z.N.A.® HP Total RNA Isolation Kit (Omega Bio-tek) was reverse-transcribed to cDNA using the AffinityScript QPCR cDNA Synthesis Kit (Agilent Technologies, Santa Clara, CA, USA) and 1000 ng of the RNA sample.

The cDNA synthesized was employed for qPCR using Brilliant III Ultra-Fast SYBR® Green QPCR Master Mix (Agilent Technologies) in a Mx3000P qPCR System (Agilent Technologies), employing a 96-well plate with 20 μL of PCR reaction per well and 10 pmol each of forward and reverse gene-specific primers. Ten genes were analyzed (see [Table 4](#molecules-24-01780-t004){ref-type="table"}). The relative gene expressions were determined using Beta-2-microglobulin (B2M) as housekeeping, and the delta-delta Ct method (2^−ΔΔCt^ method) with regard to the vehicle-treated group (i.e., the reference group). Five biological replicates were used from each group (treated and reference group). The qPCR reactions were run by duplicates and negative controls contained no cDNA, as previously reported \[[@B32-molecules-24-01780],[@B33-molecules-24-01780]\]. The GraphPad Prism software was used for statistical analyses of the relative gene expressions. The comparisons between means were performed using one-way analysis of variance (ANOVA) and Dunnett's multiple comparisons test. All statistical analyses were performed with a significance level of *p* \< 0.05.

4. Conclusions {#sec4-molecules-24-01780}
==============

In summary, we have synthesized of a number 3-acyl-2,5-*bis*(phenylamino)-1,4-benzoquinones and assessed their voltammetric values and cytotoxicities of cancer cells in vitro. The members of the series **2a**--**q** were prepared from acylbenzoquinones and phenylamines, in moderate to good yields (47--74%). The first and second half-wave potential values (E ~1/2~) of the members of the series were sensitive to the push-pull electronic effects of the substituents around the benzoquinone nucleus, as shown by the cyclic voltammograms of the aminoquinones. The preliminary results of the biological evaluation of the compounds **2a**--**q** showed interesting in vitro cytotoxic activity on cancer cells. In this context, there were two more active compounds which increased TNF gene expression, suggesting an association with an inflammatory-like response.
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![Examples of natural and synthetic antitumor active aminoquinones.](molecules-24-01780-g001){#molecules-24-01780-f001}

![General access to 3-acyl-2,5-diphenylamino-1,4-benzoquinones **2a**--**q**.](molecules-24-01780-sch001){#molecules-24-01780-sch001}

![Heteronuclear multiple bond correlations (HMBCs) of compounds **2b** and **2p.**](molecules-24-01780-g002){#molecules-24-01780-f002}

![Optimized 3D-structure of compounds **2b** and **2p.**](molecules-24-01780-g003){#molecules-24-01780-f003}

molecules-24-01780-t001_Table 1

###### 

Yield and half-wave potential (E^I,II^ ~½~) values of compounds **2a**--**q**.

![](molecules-24-01780-i001)

  Product Nº   R^1^               R^2^   R^3^   R^4^   Yield (%) ^a^   ClogP   −E^I^ ~1/2~ (mV)   −E^II^ ~1/2~ (mV)
  ------------ ------------------ ------ ------ ------ --------------- ------- ------------------ -------------------
  **2a**       CH~3~              H      H      H      64              0.14    565                1170
  **2b**       C~3~H~7~           H      H      H      56              1.21    570                1150
  **2c**       C~5~H~11~          H      H      H      57              2.05    570                1090
  **2d**       C~7~H~15~          H      H      H      59              2.88    590                910
  **2e**       3,4-(OMe)~2~Ph     H      H      H      55              1.69    560                1140
  **2f**       3,4,5-(OMe)~3~Ph   H      H      H      58              1.57    560                1120
  **2g**       Furan-2-yl         H      H      H      56              0.56    570                870
  **2h**       Thiophen-2-yl      H      H      H      60              1.93    500                1030
  **2i**       Ph                 MeO    MeO    MeO    74              1.19    800                950
  **2j**       4-MeOPh            MeO    MeO    MeO    57              1.06    740                950
  **2k**       3-OMe-4-HOPh       MeO    MeO    MeO    63              0.67    610                1010
  **2l**       Furan-2-yl         MeO    MeO    MeO    67              −0.20   790                930
  **2m**       Thiophen-2-yl      MeO    MeO    MeO    64              1.17    850                1010
  **2n**       Ph                 H      F      H      47              2.26    560                1040
  **2ñ**       4-MeOPh            H      F      H      62              2.13    710                860
  **2o**       3-MeO-4-HOPh       H      F      H      52              1.74    550                920
  **2p**       Furan-2-yl         H      F      H      49              0.88    680                950
  **2q**       Thiophen-2-yl      H      F      H      55              2.24    730                980

^a^ The products were isolated by column chromatography. Yields are based on acylhydroquinones **1a**--**q**.

molecules-24-01780-t002_Table 2

###### 

IC~50~ ± SEM (μM) values of **2a**--**q** on T24 (bladder), DU-145 (prostate), and HEK-293 kidney cells.

  Quinone   T24           DU-145        Mean value   HEK-293
  --------- ------------- ------------- ------------ -------------
  **2a**    \>100         96.0 ± 7.9    98.0         \>100
  **2b**    \>100         92.2 ± 8.7    96.1         \>100
  **2c**    16.3 ± 1.7    45.2 ± 4.5    30.7         \>100
  **2d**    34.0 ± 3.7    23.5 ± 2.1    28.7         \>100
  **2e**    58.2 ± 7.1    47.7 ± 4.2    52.9         \>100
  **2f**    51.8 ± 6.2    20.4 ± 2.1    36.1         85.8 ± 0.9
  **2g**    40.2 ± 4.0    39.9 ± 3.6    40.0         61.7 ± 4.2
  **2h**    75.6 ± 9.1    80.9 ± 9.7    78.2         \>100
  **2i**    \>100         92.9 ± 1.4    96.4         \>100
  **2j**    85.3 ± 1.9    72.4 ± 2.6    78.8         56.9 ± 5.2
  **2k**    \>100         45.9 ± 3.2    72.9         28.3 ± 1.5
  **2l**    47.1 ± 2.0    23.0 ± 2.3    35.0         33.0 ± 4.8
  **2m**    63.2 ± 0.6    48.6 ± 3.0    55.9         30.7 ± 3.1
  **2n**    74.5 ± 2.2    \>100         87.2         \>100
  **2ñ**    \>100         \>100         100.0        \>100
  **2o**    \>100         \>100         100.0        \>100
  **2p**    \>100         90.0 ± 6.4    95.0         72.8 ± 7.0
  **2q**    \>100         \>100         100          \>100
  DOX       0.46 ± 0.08   0.93 ± 0.06   0.69         4.27 ± 0.34

Cells were seeded into 96-well plates at a density of 10,000 cells/well for 24 h and then incubated for 48 h, with or without the quinone derivatives. At the end of the incubation, aliquots of cell suspensions were taken and the MTT test was performed, as described in the Materials and Methods section. Results are expressed as mean values ± SEM (μM) (*n* = 3). DOX = Doxorubicin.

molecules-24-01780-t003_Table 3

###### 

Relative expression levels of genes implicated in anti-cancer effects in T24 cells after treatment with compounds **2c** and **2d**.

  Gene Name                                                Gene Symbol   Relative Expression Levels in T24 Cells (μM)                        
  -------------------------------------------------------- ------------- ---------------------------------------------- -------------------- ------------------
  Apoptosis regulator (*BCL2*), transcript variant alpha   *BCL2*        1.00 ± 0.05                                    1.28 ± 0.15          0.80 ± 0.04
  Mechanistic target of rapamycin kinase                   *mTOR*        1.00 ± 0.04                                    0.99 ± 0.13          0.95 ± 0.02
  Glutathione S-transferase pi 1                           *GSTP1*       1.00 ± 0.06                                    0.90 ± 0.08          1.21 ± 0.04 \*
  Glutathione-disulfide reductase                          *GSR*         1.00 ± 0.05                                    0.96 ± 0.05          1.07 ± 0.04
  Cell division cycle 25A                                  *CDC25A*      1.00 ± 0.06                                    1.54 ± 0.13 \*\*\*   1.07 ± 0.03
  Tumor protein p53                                        *TP53*        1.00 ± 0.04                                    1.06 ± 0.11          1.01 ± 0.04
  v-Ha-ras Harvey rat sarcoma viral oncogene homolog       *HRAS*        1.00 ± 0.06                                    1.07 ± 0.13          1.33 ± 0.06 \*
  Histone deacetylase 3                                    *HDAC3*       1.00 ± 0.06                                    1.03 ± 0.15          1.02 ± 0.05
  Histone deacetylase 4                                    *HDAC4*       1.00 ± 0.05                                    1.08 ± 0.13          1.01 ± 0.02
  Tumor necrosis factor                                    *TNF*         1.00 ± 0.03                                    2.04 ± 0.11 \*\*\*   1.44 ± 0.10 \*\*

Cells were treated with **2c** and **2d** for 48 h. Total RNA was extracted for qPCR. The mRNA expression levels were evaluated and further normalized to B2M level and the quantification performed according to the Delta--Delta Ct method (2^−∆∆Ct^ method) with respect to the vehicle-treated group (reference group). The values represent the mean ± SEM, with *n* = 5 for each group. Significant differences, in comparison with the vehicle-treated group: \* *p* \< 0.05; \*\* *p* \< 0.01; and \*\*\* *p* \< 0.001.

molecules-24-01780-t004_Table 4

###### 

Quantitative real-time (qPCR) Primer Sequences.

  Gene Name                                              Gene Symbol   Entrez Gene ID   Forward (5′ → 3′)        Reverse (5′ → 3′)        Amplicon Size (pb)
  ------------------------------------------------------ ------------- ---------------- ------------------------ ------------------------ --------------------
  **Apoptosis**                                                                                                                           
  Apoptosis regulator (BCL2), transcript variant alpha   *BCL2*        NM_000633.2      ATGTGTGTGGAGAGCGTCAA     GAGACAGCCAGGAGAAATCAA    181
  **PI3 Kinases & Phosphatases**                                                                                                          
  Mechanistic target of rapamycin kinase                 *mTOR*        NM_004958.3      TCCGAGAGATGAGTCAAGAGG    CACCTTCCACTCCTATGAGGC    141
  **Drug Metabolism/Oxidative Stress**                                                                                                    
  Glutathione S-transferase pi 1                         *GSTP1*       NM_000852.3      CATCTACACCAACTATGAGGCG   AGCAGGGTCTCAAAAGGCTTC    81
  Glutathione-disulfide reductase                        *GSR*         NM_000637.4      CACTTGCGTGAATGTTGGATG    TGGGATCACTCGTGAAGGCT     242
  **Cell Cycle**                                                                                                                          
  Cell division cycle 25A                                *CDC25A*      NM_001789.2      TGGGCCATTGGACAGTAAAG     TCCCAACAGCTTCTGAGGTA     76
  Tumor protein p53                                      *TP53*        NM_000546.5      ACAGCTTTGAGGTGCGTGTTT    CCCTTTCTTGCGGAGATTCTCT   77
  **Ras Signaling**                                                                                                                       
  V-Ha-Ras Harvey rat sarcoma viral oncogene homolog     *HRAS*        NM_005343        GACGTGCCTGTTGGACATC      CTTCACCCGTTTGATCTGCTC    166
  **Histone Deacetylases**                                                                                                                
  Histone deacetylase 3                                  *HDAC3*       NM_003883.3      TCTGGCTTCTGCTATGTCAACG   CCCGGTCAGTGAGGTAGAAAG    136
  Histone deacetylase 4                                  *HDAC4*       NM_006037.3      AGCGTCCGTTGGATGTCAC      CCTTCTCGTGCCACAAGTCT     169
  **Inflammation**                                                                                                                        
  Tumor necrosis factor                                  *TNF*         NM_000594.3      AGAACTCACTGGGGCCTACA     GCTCCGTGTCTCAAGGAAGT     177
  **Housekeeping**                                                                                                                        
  Beta-2-microglobulin                                   *B2M*         NM_004048.2      ATGAGTATGCCTGCCGTGTGA    GGCATCTTCAAACCTCCATG     97
